Last updated: February 6, 2026
PLAN B ONE-STEP, an over-the-counter emergency contraceptive containing levonorgestrel, has maintained a significant position in the reproductive health market since its launch. Its market dynamics are driven by increasing awareness of emergency contraception, regulatory approvals, and consumer demand for accessible birth control options. Financially, the product generates substantial revenue, with growth influenced by market expansion, marketing efforts, and competitive pressures. The competitive landscape features other OTC and prescription emergency contraception options, impacting PLAN B ONE-STEP’s market share.
Market Overview
Product Details and Role
PLAN B ONE-STEP contains 1.5 mg of levonorgestrel. It was approved by the FDA in 2009 as an OTC medication for individuals aged 17 and older, expanding access to emergency contraception. The product is primarily used to prevent pregnancy after unprotected sex or contraceptive failure.
Market Size and Growth
The global emergency contraceptive market was valued at approximately USD 1.2 billion in 2022 and is projected to grow at a CAGR of 7% through 2028[1]. North America accounts for over 60% of this market, driven by high awareness and regulatory approvals expanding OTC access.
In the US, the market for OTC emergency contraceptives exceeds USD 300 million annually, with PLAN B ONE-STEP holding around 70% of OTC emergency contraceptive sales, according to IQVIA data[2].
Key Market Drivers
- Increased awareness and destigmatization of emergency contraception.
- Regulatory improvements expanding OTC availability.
- Promotion through healthcare campaigns and insurance policies that reduce barriers.
- Growing demand among adolescents and young women.
Pricing and Revenue Trends
Retail price for a single pack of PLAN B ONE-STEP averages USD 45-50 in US pharmacies. Though prices vary by location and retailer, sales volume supports robust revenue streams. Since its launch, sales volume has increased an estimated 15% annually, with occasional dips linked to regulatory or competitive changes.
Competitive Landscape
Primary competitors include off-label use of prescription drugs such as ella (ulipristal acetate) and prescription levonorgestrel products. Recently, generic formulations of levonorgestrel pills have entered the market, reducing prices and affecting margins.
Key competitors:
- Generic levonorgestrel products (lower price point)
- ella (requires prescription; 30 mg ulipristal acetate)
- Next Choice and other OTC brands in certain markets
Market share has shifted to generics, which now comprise approximately 25-30% of OTC emergency contraception sales.
Regulatory Influences
In 2013, the FDA approved the sale of levonorgestrel-based emergency contraception OTC without age restriction. In 2019, the age restriction was removed, broadening access. These regulatory changes led to a temporary surge in sales.
Recent regulatory debates involve potential OTC approval of ella, which could alter the competitive landscape. The FDA's stance on OTC access for ulipristal acetate remains under consideration.
Financial Trajectory
Revenue
- Estimated USD 300 million+ annual sales in the US (2022 figures).
- Sales growth driven by increased demand and market expansion.
- Margin analysis indicates gross margins around 50%, influenced by manufacturing and marketing costs.
Profitability
- Profit margins are sustainable due to low manufacturing costs and high consumer demand.
- Marketing investments focused on consumer awareness campaigns account for 10-15% of revenues.
- Entry of generic competitors pressures pricing strategies but maintains overall revenue levels.
Investment and R&D
- Revenue reinvestment in marketing and cost optimization.
- Limited R&D for new formulations; focus on improving existing product distribution and access.
Market Challenges
- Price competition from generics reduces profit margins.
- Potential regulatory changes introducing prescription-only status for certain formulations, which could diminish OTC sales.
- Competition from alternative contraceptives and newer OTP options.
Future Outlook
The market expects steady growth, supported by expanding OTC access and demographic shifts favoring younger consumers. Regulatory developments, especially regarding ulipristal acetate, could introduce new competitive dynamics.
Key Takeaways
- PLAN B ONE-STEP remains dominant in the OTC emergency contraception segment, with over USD 300 million annual revenue in the US.
- Market growth is driven by increased demand, expanded OTC access, and consumer awareness.
- Competition from generics and potential regulatory changes pose ongoing challenges.
- Pricing strategies are influenced by generic entry; margins remain healthy but are under pressure.
- Future growth depends on regulatory landscape shifts, marketing efforts, and consumer trends.
FAQs
- How does OTC regulation impact the market potential for PLAN B ONE-STEP?
- What is the impact of generic levonorgestrel products on the product’s revenue?
- How might future FDA rulings affect the competitive landscape?
- What demographic trends are influencing emergency contraception sales?
- How does pricing vary across different markets, and what are the profit implications?
Sources
[1] MarketResearch.com, "Global Emergency Contraceptive Market," 2022
[2] IQVIA, "US Over-the-Counter Contraceptive Sales Data," 2022
